Table 2.
Antibody | VH | VL | |||
---|---|---|---|---|---|
V | D | J | V | J | |
MH1 a | IGHV4.40 | IGHD2-4*01 | IGHJ1*01 | IGLV3.46 c | IGLJ3 |
MH2 a | IGHV3.15 | IGHD5-3*01 | IGHJ5-1*01 | IGLV3.46 c | IGLJ2 |
MH36 b | IGHV3.9 | IGHD4-2*01 | IGHJ4*01 | IGLV1.25 c | IGLJ2 |
MH49 b | IGHV4.11 | IGHD4-2*01 | IGHJ3*01 | IGLV1.27 c | IGLJx1 |
MH67 b | IGHV4.11 | IGHD4-2*01 | IGHJ3*01 | IGKV1.9 d | IGKJ2 |
MH73 a | IGHV4.11 | IGHD1-2*01 | IGHJ5-1*01 | IGKV1.52 d | IGKJ2 |
MH74 a | IGHV5.7 | IGHD3-3*01 | IGHJ5-2*02 | IGLV1.30 c | IGLJ3 |
MH75 a | IGHV3.15 | IGHD5-3*01 | IGHJ5-1*01 | IGLV3.46 c | IGLJ2 |
MH76 a | IGHV3.15 | IGHD3-1*01 | IGHJ4*01 | IGLV3.46 c | IGLJ3 |
MH77 a | IGHV4.40 | IGHD4-4*01 | IGHJ5-1*01 | IGKV1.7 d | IGKJ2 |
a Originated from the subunit-based vaccine library. b Originated from the holotoxin-based vaccine library. c λ isotype. d κ isotype.